Biomerica, Inc. (BMRA)

Over the past six months, Biomerica's stock price decreased by 10.49%. From January 2, 2025, to December 31, 2025, the share price increased by 3.96%. In the past year, the stock has seen a decrease of -7.020% and a 52-week range between $2.11 and $10.16. In December 2025, the Egyptian Drug Authority authorized Biomerica's complete portfolio of rapid screening tests for marketing and distribution in Egypt, and Biomerica announced a CMS Medicare payment rate of $300 for its inFoods® IBS Test. In November 2025, Biomerica expanded its CDMO services and reported its first-quarter fiscal 2026 financial results, with net sales of $1.4M, an improved gross margin of 31%, and a small net profit of approximately $2,000 due to a non-recurring tax credit. In October 2025, Henry Schein and Biomerica entered into a marketing services agreement for Biomerica's inFoods® IBS Test in the U.S. In June 2025, a landmark study supporting the inFoods® IBS Test as an effective personalized therapy for IBS patients was published, and another study demonstrated significant reductions in GI pain and bloating with Biomerica's inFoods® IBS in a real-world setting.

Specific detailed information regarding the demand seasonality for Biomerica, Inc.'s products and services is not explicitly provided in the search results. While seasonal patterns might exist, detailed public information on the demand seasonality for their diagnostic products and contract manufacturing services is not readily available.

Biomerica, Inc. is a global biomedical technology company specializing in the development, manufacture, and marketing of medical diagnostic and therapeutic products within the Health Technology sector, focusing on Medical Specialties, Health Care Equipment & Supplies, and Biotechnology: In Vitro & In Vivo Diagnostic Substances. The company's product portfolio is designed for the early detection and monitoring of chronic diseases and medical conditions, with key areas of focus including gastrointestinal diseases, food intolerances, diabetes, and esoteric tests. Biomerica offers In Vitro Diagnostic (IVD) Kits for analyzing samples, the InFoods® IBS Test for identifying patient-specific foods that may alleviate IBS symptoms, Helicobacter pylori (H. pylori) diagnostic products, the EZ Detect™ colorectal screening test, kidney disease screening tests, food intolerance tests, and Contract Development and Manufacturing Organization (CDMO) services.

Biomerica, Inc. has a global geographic footprint, operating through segments in Europe, North America, Asia, South America, and the Middle East. The majority of the company's revenue is generated from the European and Asian markets. The company distributes its products globally through a network of international distributors and direct sales channels, serving hospitals, clinics, laboratories, and direct-to-consumer markets.

Biomerica's brand reputation appears to be positively influenced by the publication of a landmark study supporting the inFoods® IBS Test, demonstration of significant reductions in GI pain and bloating with Biomerica's inFoods® IBS in a real-world study, authorization of Biomerica's complete screening test portfolio in Egypt, approval of the Fortel Kidney Test by the United Arab Emirates Ministry of Health and Prevention, securing a PLA Code for the InFoods® IBS Test, and expansion of its CDMO services. There is no readily available information indicating any significant negative events that have affected Biomerica, Inc.'s brand reputation in the past year.

Approximately 91.76% of Biomerica Inc. (BMRA) stock is held by retail investors and public companies, with institutional investors holding approximately 0.76% to 3.01% of the stock, and insiders owning about 6.99% to 9.96%. Major institutional owners include Vanguard Group Inc., Geode Capital Management, LLC, and BlackRock, Inc. Key individual owners (insiders) include Zackary S. Irani, Gary Lu, Allen C. Barbieri, Jane Emerson, and Gary Huff. Shareholders have experienced substantial dilution in the past year, with total shares outstanding growing by 40.2%.